E2F-8 inhibitors belong to a distinctive chemical class that specifically targets the E2F-8 protein, a member of the E2F family of transcription factors. E2F proteins play a crucial role in regulating the cell cycle, influencing processes such as DNA synthesis and cell division. E2F-8, in particular, has been identified as a key modulator in controlling cell proliferation and differentiation. In normal cellular processes, E2F-8 acts as a transcriptional repressor, dampening the expression of genes involved in cell cycle progression. However, aberrant regulation of E2F-8 has been implicated in various pathological conditions, including cancer, where its overexpression is associated with uncontrolled cell proliferation and tumor progression.
E2F-8 inhibitors represents a significant advancement in the field of molecular pharmacology. These inhibitors are designed to selectively bind to E2F-8, disrupting its transcriptional regulatory activity. By doing so, E2F-8 inhibitors aim to restore the balance of cell cycle control and impede the unbridled proliferation of cells, particularly in contexts where E2F-8 dysregulation contributes to disease states. The chemical structure of E2F-8 inhibitors is meticulously crafted to achieve high specificity for the target protein while minimizing off-target effects. As research in this area progresses, a deeper understanding of the molecular interactions between E2F-8 and its inhibitors may pave the way for novel strategies aimed at modulating cellular processes associated with conditions driven by aberrant cell cycle regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor that indirectly reduces E2F8 activity by preventing the phosphorylation of RB1, leading to cell cycle arrest. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Similar to Palbociclib, it inhibits CDK4/6, consequently blocking RB1 phosphorylation and reducing E2F8-mediated transcription. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Another CDK4/6 inhibitor that indirectly hampers E2F8 by maintaining the RB1 protein in an active, hypophosphorylated state. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Inhibits CDKs, including CDK4/6, and can indirectly decrease E2F8 activity by causing RB1-mediated cell cycle arrest. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
A CDK inhibitor that can reduce E2F transcription factor activity, including E2F8, by stabilizing the RB1-E2F complex. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Strongly inhibits multiple CDKs and may indirectly limit E2F8 activity via RB1 interaction. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
A purine derivative that inhibits CDKs and could decrease E2F8 activity by affecting RB1 phosphorylation. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Targets multiple CDKs, potentially affecting E2F8 activity through RB1-E2F regulatory control. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
Inhibits various CDKs, possibly leading to reduced E2F8 activity by enhancing RB1's inhibitory effect on E2F-regulated transcription. | ||||||